Skip to content

Sleep, Stress & Longevity

DHH-B

Magnolia-derived GABA-A modulator marketed for calm and sleep without next-day grogginess; human evidence is essentially absent.

SupplementEvidence level 1 of 5: Preclinical / anecdotalAlso: Dihydrohonokiol-B, Dihydrohonokiol, 3'-propyl-5-(2-propenyl)-[1,1'-biphenyl]-2,4'-diol

Overview

DHH-B is a derivative of honokiol, a compound from magnolia bark long used in traditional East Asian medicine. Like benzodiazepines, it is thought to enhance GABA-A receptor activity, the brain's main calming signal, but at a different binding site. In mouse studies dating to the late 1990s, it reduced anxiety-like behavior at low doses without the motor impairment, memory effects or withdrawal seen with diazepam. These findings have made it a popular supplement for stress and sleep, with many users reporting calm focus and minimal next-day sedation. However, no controlled human trials have been published, product quality varies, and tolerance can develop with nightly use. It should not be combined with alcohol or sedative medications.

Classification
Botanical-derived small molecule (magnolia bark honokiol derivative) — not a peptide
Route
Oral; sublingual (more bioavailable)
Half-life
Not well established

Mechanism of action

Primary targetGABA-A receptor (positive allosteric modulation)
  1. Oral or sublingual absorptionLipophilic compound absorbed and enters the brain.
  2. GABA-A modulationBinds an allosteric site, enhancing GABA-gated chloride flow.
  3. Neuronal hyperpolarizationIncreased chloride influx quiets overactive neurons.
  4. Limbic calmingReduced amygdala-driven anxiety signaling (rodent data).
Downstream effects
  • Reduced anxiety
  • Easier sleep onset
  • Minimal next-day sedation (reported)

Researched for

  • Generalized anxiety
  • Stress-related insomnia
  • Benzodiazepine-sparing anxiolysis

Research notes

  • Kuribara et al. (2000): dihydrohonokiol was anxiolytic in mice at low doses without benzodiazepine-like motor or amnestic effects.
  • Animal data suggest lower dependence potential than diazepam, but this is unverified in humans.
  • No published randomized human trials; dosing is based on practitioner and user experience.
  • Supplement purity and dose consistency are not independently verified.

Reported side effects

  • Mild dose-dependent sedation or drowsiness
  • Dizziness at higher doses
  • Tolerance with daily use
  • Possible dependence (lower than benzodiazepines but present)

Contraindications & cautions

  • Concurrent benzodiazepines, alcohol, opioids or other sedatives
  • Pregnancy and breastfeeding
  • Liver disease
  • Operating vehicles or machinery until response is known

Lab monitoring

  • CBC, CMP
  • Liver enzymes (AST, ALT) with regular use
  • Cortisol rhythm if stress-related
  • Thyroid panel
  • Vitamin D, RBC magnesium, B12, folate

Dosing and pricing for DHH-B

Dosing references and compound pricing are available to established patients in the secure portal after a medical evaluation.

Ready to take control of your health?

Start with a 60-minute physician evaluation, virtually in seven states or in person in Reston, Virginia.

Request a consultation 703-400-5314

Cash-pay. HSA and FSA accepted. Monday–Friday, 10 AM – 2 PM (virtual and in person).